MedTrace Logo

The Role of COX-2 Inhibition in Salt Sensitivity of Blood Pressure

NCT00624559 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 12

Last updated 2012-01-06

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to determine if the drug Celebrex changes the way the kidney gets rid of salt and maintains blood pressure.

Conditions

Interventions

DRUG

celecoxib (Celebrex)

Celecoxib (Celebrex) was administered at 100 mg, twice per day for each day of sodium diet

OTHER

Placebo

Placebo pill taken twice per day on each day of the diet

Sponsors & Collaborators

  • Christiana Care Health Services

    collaborator OTHER

  • University of Delaware

    lead OTHER

Principal Investigators

  • William B Farquhar, PhD · University of Delaware

  • Michael Stillabower, MD · Christiana Care Health Services

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
22 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2008-02-29
Primary Completion
2009-01-31
Completion
2009-01-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00624559 on ClinicalTrials.gov